drugset
drugset / Trial / NCT02006719

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

NCT02006719 ↗

Phase 2 Completed 322 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.

Timeline

Start
2013-11
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.58 mg Other

Indications

frozen shoulder